Cancer cachexia is a collection of symptoms involving progressive bodyweight loss with associated depletion of liver and skeletal muscle energy that ultimately bodes a poor prognosis in patients with cancer. Cachexia occurs in approximately 80% of patients with advanced cancer, and it is the most significant independent negative predictor of death with ~30% of cancer patients dying of cachexia. There are currently no effective treatments for cancer cachexia.

Medific Inc. has described substituted thiazolidinedione derivatives acting as sterol regulatory element binding protein (SREBP; SREBF1) inhibitors reported to be useful for the treatment of cancer, particularly brain cancer.

Shanghai Allist Pharmaceuticals Co. Ltd. has divulged EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.

Suzhou Kintor Pharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moiety covalently linked to Myc proto-oncogene protein (c-Myc), eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), zinc finger protein helios (IKZF2) and casein kinase 1 isoform α (CK1α).

Hangzhou Polymed Biopharmaceuticals Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.